Healthcare Sales & Marketing Network News: Medivation

Searching News Database: Medivation

HSMN NewsFeed - 8 Dec 2021
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 May 2021
Astellas' XTANDI(TM) (enzalutamide) Approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Nov 2020
XTANDI(R) (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 May 2020
XTANDI(R) (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 21 May 2020
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Sep 2019
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Nov 2018
ORIC Pharmaceuticals Appoints Matt Panuwat as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Oct 2018
89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 12 Feb 2018
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Jun 2017
Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Jun 2017
Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 6 Jun 2017
Axovant Strengthens Executive Team with Key Management Appointments
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 10 Apr 2017
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 30 Mar 2017
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Jan 2017
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
Biopharmaceuticals Ophthalmology Personnel

HSMN NewsFeed - 28 Sep 2016
Pfizer Completes Acquisition of Medivation
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Sep 2016
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 22 Aug 2016
Pfizer to Acquire Medivation
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 24 Mar 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Sep 2015
Tokai Pharmaceuticals Augments Commercialization Capabilities through Appointment of Lisa Taylor as Senior Vice President, Commercial Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Aug 2015
Aratana Therapeutics Elects Wendy Yarno as Chairman of the Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Apr 2014
Astellas Announces European Regulatory Submission For XTANDI(R) (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 May 2013
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Mar 2013
Labrys Biologics Announces Key Executive Appointments
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Mar 2012
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 13 Jul 2011
Medivation Names Stewart Hallett Vice President of Clinical Operations
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 10 Dec 2010
Spinal Cord Injury Patient Treated With Non-Matched Adult Stem Cells
Regenerative Medicine Neurology

HSMN NewsFeed - 7 Dec 2010
Medistem Announces New Management Team
Regenerative Medicine Personnel

HSMN NewsFeed - 30 Mar 2010
Medivation Announces Reduction in Workforce
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 Mar 2010
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Biopharmaceuticals Neurology

HSMN NewsFeed - 18 Mar 2009
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Mar 2008
Medivation Announces Senior Management Promotions
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Jan 2008
Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008
Biopharmaceuticals Neurology

HSMN NewsFeed - 15 Jan 2008
Medivation Names Rohan Palekar Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 11 Jun 2007
Medivation's Dimebon(TM) Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy
Biopharmaceuticals Neurology

HSMN NewsFeed - 19 Mar 2007
Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Disease Conference
Biopharmaceuticals Neurology

HSMN NewsFeed - 17 Jan 2007
SpectRx, Inc. Announces Management Changes
Diagnostics Personnel

HSMN NewsFeed - 17 Jan 2007
Medivation Names Lisa Taylor Vice President of Commercial Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Sep 2006
Medivation Receives FDA Permission to Begin Dimebon Huntington's Disease Trial
Biopharmaceuticals FDA Neurology

HSMN NewsFeed - 21 Sep 2006
Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study
Biopharmaceuticals Neurology

HSMN NewsFeed - 14 Sep 2006
Medivation Appoints Dr. Andrew A. Protter Vice President of Preclinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2006
Medivation Provides Update on Huntington's Disease IND
Biopharmaceuticals Neurology

Return to NewsFeed

Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 10 additional stories matching:
Medivation
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.